Proteasome inhibitors, for example, have been used to treat hematological malignancies [1], [2] and serum levels of the protease PSA (prostate specific antigen) have been used as a biomarker for monitoring prostate cancer in various contexts [3]. This evidence concerns the gene KLK3 and prostate carcinoma.